Introduction
Healthcare IB modeling tests evaluate two competencies simultaneously: your technical modeling ability (can you build a functional financial model under time pressure?) and your sector-specific analytical judgment (do you understand the healthcare assumptions that drive the model output?). Many candidates who can build a standard three-statement model or LBO fail healthcare modeling tests because they do not know how to make the healthcare-specific judgment calls the test requires. Understanding these judgment calls before the test is the highest-return preparation activity.
Archetype 1: Biotech rNPV / Pipeline Valuation
What You Receive
A prompt describing a clinical-stage biotech company with 2-4 pipeline programs at different clinical phases. You receive the therapeutic indication, current clinical phase, and possibly some market data for each program. You are asked to value the company using risk-adjusted NPV.
What They Are Testing
- Probability-of-Success Sensitivity
The single most impactful assumption in a biotech rNPV model. Small changes in the probability-of-success (POS) assumption can swing the valuation by 50-100%. A Phase 2 oncology asset with a 25% POS is worth exactly half of the same asset at 50% POS. Interviewers use the rNPV test to see whether candidates recognize this sensitivity, apply differentiated POS rates by therapeutic area and clinical phase (rather than a single generic rate), and can articulate why they chose specific assumptions.
Key judgment calls tested: (1) What probability of success to assign each pipeline program. (2) How to estimate peak sales (addressable patient population, market share, pricing). (3) What discount rate to use (and understanding that clinical risk is captured in POS, so the discount rate should reflect systematic risk only). (4) How to model the revenue ramp from launch to peak and the decline curve post-LOE.
How to Approach It
Build a modular model: one sheet per pipeline program, each with its own revenue curve and POS adjustment. Sum the probability-weighted NPVs, add net cash (or subtract net debt), and divide by fully diluted shares. The elegance is in the assumptions and the sensitivity analysis, not in complex Excel mechanics.
Archetype 2: Healthcare Services LBO
What You Receive
A prompt describing a PE acquisition of a healthcare services platform (physician practice management, dental, behavioral health, home health, or a similar vertical). You receive historical financials, payer mix data, same-store growth rates, and an add-on acquisition pipeline. You are asked to build an LBO model and calculate returns under various scenarios.
What They Are Testing
| Judgment Call | What It Tests | Common Error |
|---|---|---|
| Same-store growth assumption | Understanding of organic growth quality | Using total growth (inflated by acquisitions) |
| Payer mix sensitivity | Revenue quality analysis | Ignoring Medicare rate change risk |
| Add-on acquisition economics | Roll-up value creation modeling | Not modeling integration costs |
| Provider retention | Key-person risk | Assuming zero attrition post-acquisition |
| EBITDA adjustments | QofE awareness | Accepting adjusted EBITDA at face value |
Key judgment calls tested: (1) How to model organic same-store growth versus acquisition-driven growth. (2) How to sensitize to payer mix shifts (what happens if Medicare rates decline 5%?). (3) How to model add-on acquisition economics (entry multiples, synergies, integration costs). (4) How to structure the capital stack, including any MSO-PC structural considerations. (5) How to model rollover equity for physician-owners who are staying involved post-acquisition.
How to Approach It
Build a standard LBO framework but layer in healthcare-specific revenue drivers. Revenue should be modeled bottom-up: patient volumes x reimbursement rates by payer, with same-store growth applied to existing locations and pro forma revenue added for planned add-ons. The exit should consider both strategic and secondary buyout scenarios, since healthcare services platforms can exit to larger PE funds, health systems, or insurers.
Archetype 3: Medical Device DCF
What You Receive
A prompt describing a medical device company with 1-3 product lines. You receive market data on procedure volumes, ASP trends, and competitive market share. You are asked to build a DCF and assess fair value.
What They Are Testing
Key judgment calls tested: (1) How to model revenue as procedure volumes x ASP x market share, with each component having its own growth driver. (2) How to handle ASP erosion (competitive pressure drives 2-5% annual ASP decline for mature devices). (3) How to model the impact of new product launches on market share. (4) Whether the terminal value assumption is reasonable given the company's competitive position and technology lifecycle.
How to Approach It
Build a revenue model that decomposes revenue into its component drivers (volume, price, share) rather than applying a single growth rate. The model should capture the cross-currents in device revenue: favorable procedure volume trends versus unfavorable ASP erosion, with market share gains from new products potentially offsetting both.
General Modeling Test Advice
Regardless of the archetype, healthcare modeling tests prioritize judgment over mechanical complexity. A clean, assumption-driven model with well-reasoned healthcare-specific inputs will score higher than an elaborate model with generic assumptions. If you have limited time, spend it on the assumptions page and the sensitivity analysis, not on formatting.
The next article covers how to pitch a healthcare stock, adapting the stock pitch framework for each healthcare sub-sector.
Free Interview PDF Guide